Free Trial
Final Hours! Save $100 on MarketBeat All Access Before 11:59 PM
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149 Tonight
Claim MarketBeat All Access Sale Promotion

CVS Health (CVS) Financials

CVS Health logo
$93.24 -0.02 (-0.02%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$93.61 +0.37 (+0.40%)
As of 05/22/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for CVS Health

Annual Income Statements for CVS Health

This table shows CVS Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
5,237 5,317 6,622 -594 6,634 7,179 8,001 4,311 8,344 4,614 1,768
Consolidated Net Income / (Loss)
5,239 5,319 6,623 -596 6,631 7,192 7,989 4,327 8,368 4,586 1,728
Net Income / (Loss) Continuing Operations
5,230 5,320 6,631 -596 6,631 7,201 7,989 4,327 8,368 4,586 1,728
Total Pre-Tax Income
8,616 8,637 8,268 1,406 8,997 9,770 10,537 5,836 11,173 6,148 2,136
Total Operating Income
9,475 10,386 9,538 4,021 11,987 13,911 13,310 7,954 13,743 8,516 4,660
Total Gross Profit
26,528 31,013 28,528 31,538 45,528 49,046 52,120 125,575 140,678 166,522 180,900
Total Revenue
153,290 177,546 184,786 194,579 256,776 268,706 292,111 322,467 357,776 372,809 402,067
Operating Revenue
153,290 177,546 184,786 194,579 256,776 268,706 292,111 322,467 357,776 372,809 402,067
Total Cost of Revenue
126,762 146,533 156,258 163,041 211,248 219,660 239,991 196,892 217,098 206,287 221,167
Operating Cost of Revenue
126,762 146,533 156,258 163,041 211,248 219,660 239,991 196,892 217,098 206,287 221,167
Total Operating Expenses
17,053 20,627 18,990 27,517 33,541 35,135 38,810 117,621 126,935 158,006 176,240
Selling, General & Admin Expense
- 18,448 18,809 - 33,310 35,135 37,021 38,212 39,832 41,706 44,977
Other Operating Expenses / (Income)
17,053 2,179 - 21,368 - - - 71,073 86,247 115,121 125,538
Impairment Charge
- 0.00 181 6,149 231 0.00 1,789 2,533 349 0.00 5,725
Restructuring Charge
- - - - - - 0.00 0.00 507 1,179 0.00
Total Other Income / (Expense), net
-859 -1,749 -1,270 -2,615 -2,990 -4,141 -2,773 -2,118 -2,570 -2,368 -2,524
Interest Expense
838 1,721 1,062 2,619 3,114 4,347 2,955 2,287 2,658 2,467 3,119
Interest & Investment Income
- - - - - - - - 0.00 0.00 483
Other Income / (Expense), net
-21 -28 -208 4.00 124 206 182 169 88 99 112
Income Tax Expense
3,386 3,317 1,637 2,002 2,366 2,569 2,548 1,509 2,805 1,562 408
Net Income / (Loss) Attributable to Noncontrolling Interest
2.00 2.00 1.00 -2.00 -3.00 13 -12 16 24 -28 -40
Basic Earnings per Share
$4.66 $4.93 $6.47 ($0.57) $5.10 $5.48 $6.07 $3.29 $6.49 $3.67 $1.40
Weighted Average Basic Shares Outstanding
1.12B 1.07B 1.02B 1.04B 1.30B 1.31B 1.32B 1.31B 1.29B 1.26B 1.27B
Diluted Earnings per Share
$4.63 $4.90 $6.44 ($0.57) $5.08 $5.46 $6.02 $3.26 $6.47 $3.66 $1.39
Weighted Average Diluted Shares Outstanding
1.13B 1.08B 1.02B 1.04B 1.31B 1.31B 1.33B 1.32B 1.29B 1.26B 1.27B
Weighted Average Basic & Diluted Shares Outstanding
1.12B 1.08B 1.02B 1.04B 1.30B 1.31B 1.31B 1.28B 1.26B 1.26B 1.27B
Cash Dividends to Common per Share
$1.40 $1.70 $2.00 $2.00 $2.00 $2.00 $2.00 $2.20 $2.42 $2.66 $2.66

Quarterly Income Statements for CVS Health

This table shows CVS Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders
2,261 2,046 1,113 1,770 87 1,644 1,779 1,021 -3,975 2,943 2,943
Consolidated Net Income / (Loss)
2,265 2,047 1,124 1,768 71 1,623 1,782 1,013 -3,990 2,923 2,957
Net Income / (Loss) Continuing Operations
2,265 2,047 1,124 1,768 71 1,623 1,782 1,013 -3,990 2,923 2,957
Total Pre-Tax Income
3,019 2,705 1,580 2,337 105 2,126 2,617 1,647 -3,482 1,354 3,938
Total Operating Income
3,690 3,373 2,271 3,045 832 2,368 3,374 2,381 -3,207 2,112 4,680
Total Gross Profit
35,076 56,842 40,364 41,236 42,480 70,245 43,531 44,910 45,826 46,633 44,982
Total Revenue
89,764 93,813 88,437 91,234 95,428 97,710 94,588 98,915 102,871 105,693 100,426
Operating Revenue
89,764 93,813 88,437 91,234 95,428 97,710 94,588 98,915 102,871 105,693 100,426
Total Cost of Revenue
54,688 36,971 48,073 49,998 52,948 27,465 51,057 54,005 57,045 59,060 55,444
Operating Cost of Revenue
54,688 36,971 48,073 49,998 52,948 27,465 51,057 54,005 57,045 59,060 55,444
Total Operating Expenses
31,386 53,469 38,093 38,191 41,648 67,877 40,157 42,529 49,033 44,521 40,302
Selling, General & Admin Expense
9,876 10,503 10,290 10,338 10,557 10,421 11,022 11,212 11,288 11,455 10,944
Other Operating Expenses / (Income)
21,499 - 27,803 27,853 29,922 - 29,135 31,317 32,020 33,066 29,358
Total Other Income / (Expense), net
-671 -668 -691 -708 -727 -242 -757 -734 -275 -758 -742
Interest Expense
693 690 716 732 752 267 785 763 784 787 774
Other Income / (Expense), net
22 22 25 24 25 25 28 29 26 29 32
Income Tax Expense
754 658 456 569 34 503 835 634 508 -1,569 981
Net Income / (Loss) Attributable to Noncontrolling Interest
4.00 1.00 11 -2.00 -16 -21 3.00 -8.00 -15 -20 14
Basic Earnings per Share
$1.76 $1.59 $0.88 $1.41 $0.07 $1.31 $1.41 $0.81 ($3.13) $2.31 $2.31
Weighted Average Basic Shares Outstanding
1.29B 1.29B 1.26B 1.26B 1.26B 1.26B 1.26B 1.27B 1.27B 1.27B 1.27B
Diluted Earnings per Share
$1.75 $1.59 $0.88 $1.41 $0.07 $1.30 $1.41 $0.80 ($3.13) $2.31 $2.30
Weighted Average Diluted Shares Outstanding
1.29B 1.29B 1.27B 1.26B 1.26B 1.26B 1.26B 1.27B 1.27B 1.27B 1.28B
Weighted Average Basic & Diluted Shares Outstanding
1.29B 1.26B 1.26B 1.26B 1.26B 1.26B 1.27B 1.27B 1.27B 1.27B 1.28B
Cash Dividends to Common per Share
$0.61 - $0.67 $0.67 - - $0.67 $0.67 - - $0.67

Annual Cash Flow Statements for CVS Health

This table details how cash moves in and out of CVS Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-22 912 -1,621 2,399 1,855 2,635 1,648 614 -4,780 359 -172
Net Cash From Operating Activities
8,539 10,141 8,007 8,865 12,848 15,865 18,265 16,177 13,426 9,107 10,639
Net Cash From Continuing Operating Activities
8,539 7,942 8,007 8,865 12,848 15,865 18,265 16,177 13,426 9,107 10,639
Net Income / (Loss) Continuing Operations
5,239 5,319 6,623 -596 6,631 7,192 7,989 4,327 8,368 4,586 1,728
Consolidated Net Income / (Loss)
5,239 5,319 6,623 -596 6,631 7,192 7,989 4,327 8,368 4,586 1,728
Depreciation Expense
2,092 2,475 2,479 2,718 4,371 4,441 4,486 4,224 4,366 4,597 4,606
Non-Cash Adjustments To Reconcile Net Income
216 -1,199 655 6,768 1,001 1,643 2,335 2,837 1,353 387 5,677
Changes in Operating Assets and Liabilities, net
992 1,347 -1,750 -25 845 2,589 3,455 4,789 -661 -463 -1,372
Net Cash From Investing Activities
-13,420 -2,470 -2,877 -43,285 -3,339 -5,534 -5,261 -5,047 -20,889 -7,613 -5,871
Net Cash From Continuing Investing Activities
-13,420 -2,470 -2,877 -43,285 -3,339 -5,534 -5,261 -5,047 -20,889 -7,613 -5,871
Purchase of Property, Plant & Equipment
-2,367 -2,224 -1,918 -2,037 -2,457 -2,437 -2,520 -2,727 -3,031 -2,781 -2,832
Acquisitions
-11,475 -524 -1,181 -42,226 -444 -866 -146 -139 -16,612 -95 -436
Purchase of Investments
-267 -80 -137 -692 -7,534 -9,639 -9,963 -7,746 -9,043 -15,191 -15,012
Sale and/or Maturity of Investments
654 321 326 817 7,049 6,467 7,246 6,729 7,729 10,353 12,383
Other Investing Activities, net
- 37 33 21 47 101 122 85 68 101 26
Net Cash From Financing Activities
4,879 -6,761 -6,751 36,819 -7,654 -7,696 -11,356 -10,516 2,683 -1,135 -4,940
Net Cash From Continuing Financing Activities
4,879 -6,761 -6,751 36,819 -7,654 -7,696 -11,356 -10,516 2,683 -1,135 -4,940
Repayment of Debt
-3,590 -4,074 -599 -6,078 -8,860 -15,199 -10,099 -4,290 -8,167 -2,828 -5,748
Repurchase of Common Equity
-5,001 -4,461 -4,361 - - 0.00 0.00 -3,500 -2,012 -3,023 0.00
Payment of Dividends
-1,576 -1,879 -2,049 -2,038 -2,603 -2,624 -2,625 -2,907 -3,132 -3,373 -3,397
Issuance of Debt
14,805 3,455 0.00 44,344 3,736 9,958 987 0.00 15,898 7,913 3,969
Other Financing Activities, net
241 198 258 591 73 169 381 181 96 176 236
Cash Interest Paid
629 1,140 -1,072 2,803 2,954 2,904 2,469 2,239 2,418 2,909 2,991
Cash Income Taxes Paid
3,274 3,060 -2,909 2,383 2,717 2,929 3,195 4,116 3,524 1,703 2,166

Quarterly Cash Flow Statements for CVS Health

This table details how cash moves in and out of CVS Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents
-752 -4,850 1,582 2,713 -5,680 1,744 1,462 1,679 -2,673 -640 1,057
Net Cash From Operating Activities
2,716 -2,636 4,903 3,089 -745 1,860 4,556 1,897 796 3,390 4,249
Net Cash From Continuing Operating Activities
2,803 -2,636 4,903 3,430 -1,086 1,860 4,556 1,897 796 3,390 4,249
Net Income / (Loss) Continuing Operations
2,265 2,047 1,124 1,768 71 1,623 1,782 1,013 -3,990 2,923 2,957
Consolidated Net Income / (Loss)
2,265 2,047 1,124 1,768 71 1,623 1,782 1,013 -3,990 2,923 2,957
Depreciation Expense
1,127 1,134 1,138 1,151 1,161 1,147 1,154 1,171 1,134 1,147 1,115
Non-Cash Adjustments To Reconcile Net Income
306 740 137 133 973 -856 362 136 5,380 -201 266
Changes in Operating Assets and Liabilities, net
-895 -6,557 2,504 378 -3,291 -54 1,258 -423 -1,728 -479 -89
Net Cash From Investing Activities
-771 -1,242 -2,094 -1,625 -3,347 -547 -762 -1,024 -2,087 -1,998 -874
Net Cash From Continuing Investing Activities
-771 -1,242 -2,094 -1,625 -3,347 -547 -762 -1,024 -2,087 -1,998 -874
Purchase of Property, Plant & Equipment
-545 -911 -705 -638 -670 -768 -743 -607 -698 -784 -849
Acquisitions
-18 -120 -25 -48 -12 -10 -20 -119 -290 -7.00 -5.00
Purchase of Investments
-2,126 -2,418 -3,545 -3,236 -5,896 -2,514 -3,552 -3,634 -3,859 -3,967 -4,186
Sale and/or Maturity of Investments
1,907 2,182 2,153 2,265 3,216 2,719 3,534 3,332 2,774 2,743 4,159
Other Investing Activities, net
11 25 28 32 15 26 19 4.00 -14 17 7.00
Net Cash From Financing Activities
-2,697 -972 -1,227 1,249 -1,588 431 -2,332 806 -1,382 -2,032 -2,318
Net Cash From Continuing Financing Activities
-2,697 -972 -1,227 1,249 -1,588 431 -2,332 806 -1,382 -2,032 -2,318
Repayment of Debt
-1,036 -223 2,468 -16 -1,061 -1,700 -1,625 1,739 -4,602 -1,260 -1,565
Payment of Dividends
-779 -779 -840 -858 -837 -838 -840 -866 -846 -845 -847
Other Financing Activities, net
115 29 172 -120 109 15 133 -67 97 73 94
Cash Interest Paid
918 369 1,043 349 999 518 1,012 472 1,045 462 1,091
Cash Income Taxes Paid
837 908 63 666 700 274 138 725 305 998 -337

Annual Balance Sheets for CVS Health

This table presents CVS Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
92,437 94,462 95,131 196,456 222,449 230,715 232,999 228,275 249,728 253,215 253,538
Total Current Assets
29,158 31,042 31,229 45,243 50,302 56,369 60,008 65,633 67,858 68,645 74,714
Cash & Equivalents
2,459 3,371 1,696 4,059 5,683 7,854 9,408 12,945 8,196 8,586 8,453
Short-Term Investments
88 87 111 2,522 2,373 3,000 3,117 2,778 3,259 2,407 2,145
Accounts Receivable
11,888 12,164 13,181 17,631 19,617 21,742 24,431 27,276 35,227 36,469 39,779
Inventories, net
14,001 14,760 15,296 16,450 17,516 18,496 17,760 19,090 18,025 18,107 19,246
Other Current Assets
722 660 945 4,581 5,113 5,277 5,292 2,636 3,151 3,076 5,091
Plant, Property, & Equipment, net
9,855 10,175 10,292 11,349 12,044 12,606 12,896 0.00 13,183 12,993 13,083
Total Noncurrent Assets
53,424 53,245 53,610 139,864 160,103 161,740 160,095 162,642 168,687 171,577 165,741
Long-Term Investments
- - 112 15,732 17,314 20,812 23,025 21,096 23,019 28,934 32,669
Goodwill
38,106 38,249 38,451 78,678 79,749 79,552 79,121 78,150 91,272 91,272 85,478
Intangible Assets
13,878 13,511 13,630 36,524 33,121 31,142 29,026 24,803 29,234 27,323 25,508
Other Noncurrent Operating Assets
1,440 1,485 1,417 8,930 29,919 30,234 28,923 38,593 25,162 24,048 22,086
Total Liabilities & Shareholders' Equity
92,437 94,462 95,131 196,456 222,449 230,715 232,999 228,275 249,728 253,215 253,538
Total Liabilities
55,195 57,628 57,436 137,913 158,279 161,014 157,618 156,506 173,092 177,485 178,156
Total Current Liabilities
23,169 26,250 30,648 44,009 53,303 62,017 67,807 69,421 79,189 84,609 88,692
Short-Term Debt
1,197 1,916 4,821 1,985 3,781 5,440 4,205 1,778 2,972 5,743 4,068
Accounts Payable
7,490 7,946 8,863 8,925 10,492 11,138 12,544 14,838 14,897 15,892 17,641
Accrued Expenses
6,829 6,937 6,581 10,711 12,133 14,243 17,670 18,745 23,515 20,810 22,387
Other Current Liabilities
7,653 9,451 10,383 22,388 26,897 31,196 33,388 33,832 37,805 42,164 44,596
Total Noncurrent Liabilities
32,026 31,378 26,788 93,904 104,976 98,997 89,811 87,085 93,903 92,876 89,464
Long-Term Debt
26,267 25,615 22,181 71,444 64,699 59,207 51,971 50,476 58,638 60,527 60,502
Capital Lease Obligations
- - - - - 18,757 18,177 16,800 16,034 14,899 13,643
Noncurrent Deferred & Payable Income Tax Liabilities
4,217 4,214 2,996 7,677 7,294 6,794 6,270 4,016 4,311 3,806 3,832
Other Noncurrent Operating Liabilities
1,542 1,549 1,611 14,783 32,983 14,239 13,393 15,793 14,920 13,644 11,487
Total Equity & Noncontrolling Interests
37,203 36,834 37,695 58,543 64,170 69,701 75,381 71,769 76,636 75,730 75,382
Total Preferred & Common Equity
37,196 36,830 37,691 58,225 63,864 69,389 75,075 71,469 76,461 75,560 75,214
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
37,196 36,830 37,691 58,225 63,864 69,389 75,075 71,469 76,461 75,560 75,214
Common Stock
30,965 31,635 32,096 45,440 45,972 46,513 47,377 48,193 48,992 49,661 50,402
Retained Earnings
35,506 38,983 43,556 40,911 45,108 49,640 54,906 56,398 61,604 62,837 61,196
Treasury Stock
-28,886 -33,452 -37,796 -28,228 -28,235 -28,178 -28,173 -31,858 -33,838 -36,818 -36,790
Accumulated Other Comprehensive Income / (Loss)
-358 -305 -165 102 1,019 1,414 965 -1,264 -297 -120 406
Noncontrolling Interest
7.00 4.00 4.00 318 306 312 306 300 175 170 168

Quarterly Balance Sheets for CVS Health

This table presents CVS Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets
250,071 251,306 249,728 249,743 252,481 252,427 253,215 255,585 258,343 255,327 252,974
Total Current Assets
67,756 70,143 67,858 67,473 69,952 67,343 68,645 73,191 75,649 77,109 74,817
Cash & Equivalents
13,807 13,043 8,196 9,801 12,507 6,875 8,586 10,076 11,787 9,098 9,542
Short-Term Investments
3,080 3,145 3,259 3,288 3,755 2,805 2,407 2,578 2,386 2,134 2,260
Accounts Receivable
29,546 32,927 35,227 32,217 32,385 36,179 36,469 39,625 40,651 43,857 40,992
Inventories, net
17,291 17,954 18,025 16,346 16,068 17,649 18,107 17,385 17,447 18,962 17,770
Other Current Assets
3,412 3,074 3,151 5,821 5,237 3,835 3,076 3,527 3,378 3,058 4,253
Plant, Property, & Equipment, net
13,001 13,022 13,183 13,037 13,032 12,728 12,993 12,856 12,825 12,838 13,037
Total Noncurrent Assets
169,314 168,141 168,687 169,233 169,497 172,356 171,577 169,538 169,869 165,380 165,120
Long-Term Investments
22,114 21,667 23,019 24,074 25,028 28,939 28,934 28,906 29,858 31,553 32,407
Goodwill
91,260 91,261 91,272 91,272 91,272 91,272 91,272 91,203 91,203 85,478 85,478
Intangible Assets
30,118 29,624 29,234 28,770 28,311 27,817 27,323 26,570 26,224 25,984 25,070
Other Noncurrent Operating Assets
25,822 25,589 25,162 25,117 24,886 24,328 24,048 22,859 22,584 22,365 22,165
Total Liabilities & Shareholders' Equity
250,071 251,306 249,728 249,743 252,481 252,427 253,215 255,585 258,343 255,327 252,974
Total Liabilities
177,069 176,796 173,092 175,593 177,370 177,321 177,485 178,475 180,792 182,217 175,337
Total Current Liabilities
79,206 81,553 79,189 83,319 81,386 84,627 84,609 88,961 94,162 92,695 86,406
Short-Term Debt
2,402 2,132 2,972 6,450 3,731 5,710 5,743 5,670 9,200 5,328 2,580
Accounts Payable
13,367 14,874 14,897 13,717 14,416 15,713 15,892 16,534 17,258 17,764 16,922
Accrued Expenses
22,831 22,571 23,515 22,350 21,163 20,174 20,810 22,369 23,101 23,415 22,258
Other Current Liabilities
40,398 41,976 37,805 40,802 42,076 43,030 42,164 44,388 44,603 46,188 44,646
Total Noncurrent Liabilities
97,863 95,243 93,903 92,274 95,984 92,694 92,876 89,514 86,630 89,522 88,931
Long-Term Debt
61,419 59,782 58,638 57,694 62,643 59,824 60,527 59,040 57,290 60,508 60,531
Capital Lease Obligations
16,609 16,441 16,034 - 15,537 15,258 14,899 14,594 14,328 14,007 13,330
Noncurrent Deferred & Payable Income Tax Liabilities
4,588 4,250 4,311 4,184 4,052 3,632 3,806 3,664 3,603 3,547 3,771
Other Noncurrent Operating Liabilities
15,247 14,770 14,920 30,396 13,752 13,980 13,644 12,216 11,409 11,460 11,299
Total Equity & Noncontrolling Interests
73,002 74,510 76,636 74,150 75,111 75,106 75,730 77,110 77,551 73,110 77,637
Total Preferred & Common Equity
72,726 74,337 76,461 73,968 74,930 74,944 75,560 76,929 77,379 72,928 77,456
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
72,726 74,337 76,461 73,968 74,930 74,944 75,560 76,929 77,379 72,928 77,456
Common Stock
48,649 48,829 48,992 49,209 49,371 49,510 49,661 49,837 50,020 50,181 50,679
Retained Earnings
58,868 60,343 61,604 61,873 62,797 62,038 62,837 63,768 63,936 59,107 63,282
Treasury Stock
-33,933 -33,831 -33,838 -36,773 -36,919 -36,813 -36,818 -36,735 -36,849 -36,776 -36,706
Accumulated Other Comprehensive Income / (Loss)
-858 -1,004 -297 -341 -319 209 -120 59 272 416 201
Noncontrolling Interest
276 173 175 182 181 162 170 181 172 182 181

Annual Metrics And Ratios for CVS Health

This table displays calculated financial ratios and metrics derived from CVS Health's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
9.99% 15.82% 4.08% 5.30% 31.96% 4.65% 8.71% 10.39% 10.95% 4.20% 7.85%
EBITDA Growth
7.60% 11.15% -7.98% -42.90% 144.43% 12.60% -3.13% -31.32% 47.38% -27.39% -29.02%
EBIT Growth
7.44% 9.56% -9.92% -56.86% 200.89% 16.56% -4.43% -39.79% 70.27% -37.71% -44.61%
NOPAT Growth
8.04% 11.23% 19.57% -122.28% 618.32% 16.06% -1.58% -41.56% 74.53% -38.28% -40.65%
Net Income Growth
12.81% 1.53% 24.52% -109.00% 1,212.58% 8.46% 11.08% -45.84% 93.39% -45.20% -62.32%
EPS Growth
16.92% 5.83% 31.43% -108.85% 991.23% 7.48% 10.26% -45.85% 98.47% -43.43% -62.02%
Operating Cash Flow Growth
4.94% 18.76% -21.04% 10.72% 44.93% 23.48% 15.13% -11.43% -17.01% -32.17% 16.82%
Free Cash Flow Firm Growth
-294.53% 194.79% -24.46% -940.79% 123.08% -134.83% 544.11% -3.40% -136.93% 248.43% 13.36%
Invested Capital Growth
28.59% -2.01% 3.07% 74.68% -2.17% 13.20% -5.97% -9.51% 15.95% -2.37% -5.68%
Revenue Q/Q Growth
2.74% 2.81% 1.32% 3.19% 5.10% 1.00% 2.47% 2.30% 2.87% 1.06% 2.03%
EBITDA Q/Q Growth
4.54% 2.30% 0.91% -23.86% 18.12% -2.36% -1.33% 11.49% -1.17% -6.96% -2.62%
EBIT Q/Q Growth
4.51% 2.39% 1.22% -36.34% 22.68% -3.36% -1.41% 19.37% -2.17% -10.42% -5.02%
NOPAT Q/Q Growth
5.14% 3.10% 31.90% -135.60% 36.95% -2.86% -0.63% 14.82% -1.49% -10.41% 421.04%
Net Income Q/Q Growth
3.52% 4.07% 31.33% -119.15% 48.48% -9.66% 5.44% 27.94% -3.29% -8.46% 303.74%
EPS Q/Q Growth
4.28% 5.15% 33.61% -118.94% 51.19% -9.75% 5.24% 29.88% -3.00% -7.34% 265.79%
Operating Cash Flow Q/Q Growth
3.33% -13.46% -21.99% 41.84% 1.22% 6.25% 2.46% -26.91% -4.85% 97.51% 16.80%
Free Cash Flow Firm Q/Q Growth
-35.27% 6.66% -28.89% -1,058.49% 118.18% -111.95% 7.34% 290.07% -4.52% 90.52% 32.92%
Invested Capital Q/Q Growth
1.25% 0.80% 8.06% 89.67% -14.82% 16.99% 16.75% 4.75% 4.17% -0.26% 0.15%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
17.31% 17.47% 15.44% 16.21% 17.73% 18.25% 17.84% 38.94% 39.32% 44.67% 44.99%
EBITDA Margin
7.53% 7.23% 6.39% 3.47% 6.42% 6.91% 6.15% 3.83% 5.09% 3.54% 2.33%
Operating Margin
6.18% 5.85% 5.16% 2.07% 4.67% 5.18% 4.56% 2.47% 3.84% 2.28% 1.16%
EBIT Margin
6.17% 5.83% 5.05% 2.07% 4.72% 5.25% 4.62% 2.52% 3.87% 2.31% 1.19%
Profit (Net Income) Margin
3.42% 3.00% 3.58% -0.31% 2.58% 2.68% 2.73% 1.34% 2.34% 1.23% 0.43%
Tax Burden Percent
60.81% 61.58% 80.10% -42.39% 73.70% 73.61% 75.82% 74.14% 74.89% 74.59% 80.90%
Interest Burden Percent
91.14% 83.38% 88.62% 34.93% 74.29% 69.21% 78.10% 71.85% 80.78% 71.36% 44.76%
Effective Tax Rate
39.30% 38.40% 19.80% 142.39% 26.30% 26.29% 24.18% 25.86% 25.11% 25.41% 19.10%
Return on Invested Capital (ROIC)
10.41% 10.40% 12.37% -1.98% 8.14% 8.97% 8.57% 5.42% 9.23% 5.37% 3.32%
ROIC Less NNEP Spread (ROIC-NNEP)
7.51% 5.99% 8.19% 0.93% 3.47% 2.51% 3.92% 0.96% 4.07% 1.18% -2.04%
Return on Net Nonoperating Assets (RNNOA)
3.52% 3.96% 5.40% 0.74% 2.66% 1.78% 2.45% 0.46% 2.05% 0.65% -1.03%
Return on Equity (ROE)
13.93% 14.36% 17.77% -1.24% 10.81% 10.74% 11.01% 5.88% 11.28% 6.02% 2.29%
Cash Return on Invested Capital (CROIC)
-14.61% 12.43% 9.34% -56.35% 10.34% -3.42% 14.72% 15.41% -5.55% 7.76% 9.16%
Operating Return on Assets (OROA)
11.35% 11.08% 9.84% 2.76% 5.78% 6.23% 5.82% 3.52% 5.79% 3.43% 1.88%
Return on Assets (ROA)
6.29% 5.69% 6.99% -0.41% 3.17% 3.17% 3.45% 1.88% 3.50% 1.82% 0.68%
Return on Common Equity (ROCE)
13.92% 14.35% 17.77% -1.23% 10.75% 10.70% 10.97% 5.86% 11.24% 6.01% 2.28%
Return on Equity Simple (ROE_SIMPLE)
14.08% 14.44% 17.57% -1.02% 10.38% 10.36% 10.64% 6.05% 10.94% 6.07% 0.00%
Net Operating Profit after Tax (NOPAT)
5,751 6,397 7,650 -1,704 8,835 10,253 10,091 5,897 10,293 6,352 3,770
NOPAT Margin
3.75% 3.60% 4.14% -0.88% 3.44% 3.82% 3.45% 1.83% 2.88% 1.70% 0.94%
Net Nonoperating Expense Percent (NNEP)
2.90% 4.40% 4.18% -2.91% 4.68% 6.45% 4.64% 4.46% 5.15% 4.19% 5.36%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - 4.19% 6.67% 4.05% 2.45%
Cost of Revenue to Revenue
82.69% 82.53% 84.56% 83.79% 82.27% 81.75% 82.16% 61.06% 60.68% 55.33% 55.01%
SG&A Expenses to Revenue
0.00% 10.39% 10.18% 0.00% 12.97% 13.08% 12.67% 11.85% 11.13% 11.16% 11.19%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
11.12% 11.62% 10.28% 14.14% 13.06% 13.08% 13.29% 36.48% 35.48% 42.38% 43.83%
Earnings before Interest and Taxes (EBIT)
9,454 10,358 9,330 4,025 12,111 14,117 13,492 8,123 13,831 8,615 4,772
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
11,546 12,833 11,809 6,743 16,482 18,558 17,978 12,347 18,197 13,212 9,378
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.28 1.82 1.59 0.96 1.32 1.16 1.67 1.57 1.26 0.74 1.33
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.55 0.38 0.32 0.29 0.33 0.30 0.43 0.35 0.27 0.15 0.25
Price to Earnings (P/E)
16.17 12.60 9.06 0.00 12.66 11.17 15.65 26.08 11.54 12.09 56.52
Dividend Yield
1.83% 2.71% 3.38% 3.63% 3.10% 3.27% 2.11% 2.57% 3.23% 6.00% 3.38%
Earnings Yield
6.18% 7.93% 11.04% 0.00% 7.90% 8.96% 6.39% 3.83% 8.66% 8.27% 1.77%
Enterprise Value to Invested Capital (EV/IC)
1.76 1.50 1.36 0.98 1.19 1.09 1.44 1.40 1.17 0.83 1.22
Enterprise Value to Revenue (EV/Rev)
0.72 0.51 0.46 0.55 0.50 0.49 0.56 0.45 0.39 0.26 0.34
Enterprise Value to EBITDA (EV/EBITDA)
9.50 7.10 7.21 15.95 7.73 7.12 9.14 11.74 7.67 7.36 14.40
Enterprise Value to EBIT (EV/EBIT)
11.60 8.79 9.12 26.72 10.52 9.37 12.18 17.85 10.10 11.28 28.30
Enterprise Value to NOPAT (EV/NOPAT)
19.06 14.24 11.12 0.00 14.42 12.90 16.28 24.58 13.57 15.30 35.82
Enterprise Value to Operating Cash Flow (EV/OCF)
12.84 8.98 10.63 12.13 9.92 8.33 9.00 8.96 10.40 10.67 12.69
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 11.91 14.72 0.00 11.36 0.00 9.47 8.65 0.00 10.58 12.97
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.74 0.75 0.72 1.25 1.07 1.20 0.99 0.96 1.01 1.07 1.04
Long-Term Debt to Equity
0.71 0.70 0.59 1.22 1.01 1.12 0.93 0.94 0.97 1.00 0.98
Financial Leverage
0.47 0.66 0.66 0.79 0.77 0.71 0.62 0.48 0.50 0.55 0.50
Leverage Ratio
2.22 2.52 2.54 3.03 3.41 3.39 3.20 3.13 3.22 3.30 3.35
Compound Leverage Factor
2.02 2.10 2.25 1.06 2.54 2.34 2.50 2.25 2.60 2.36 1.50
Debt to Total Capital
42.44% 42.77% 41.74% 55.64% 51.62% 54.48% 49.66% 49.04% 50.33% 51.73% 50.92%
Short-Term Debt to Total Capital
1.85% 2.98% 7.45% 1.50% 2.85% 3.55% 2.81% 1.26% 1.93% 3.66% 2.65%
Long-Term Debt to Total Capital
40.59% 39.80% 34.28% 54.14% 48.77% 50.92% 46.85% 47.77% 48.40% 48.07% 48.27%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.07% 0.01% 0.01% 0.24% 0.23% 0.20% 0.20% 0.21% 0.11% 0.11% 0.11%
Common Equity to Total Capital
57.48% 57.22% 58.26% 44.12% 48.14% 45.32% 50.14% 50.75% 49.56% 48.16% 48.97%
Debt to EBITDA
2.38 2.15 2.29 10.89 4.15 4.49 4.14 5.59 4.27 6.14 8.34
Net Debt to EBITDA
2.16 1.88 2.12 7.58 2.62 2.79 2.16 2.61 2.37 3.12 3.73
Long-Term Debt to EBITDA
2.28 2.00 1.88 10.60 3.93 4.20 3.90 5.45 4.10 5.71 7.91
Debt to NOPAT
4.78 4.30 3.53 -43.08 7.75 8.13 7.37 11.71 7.54 12.78 20.75
Net Debt to NOPAT
4.33 3.76 3.28 -29.99 4.88 5.05 3.85 5.47 4.19 6.49 9.27
Long-Term Debt to NOPAT
4.57 4.00 2.90 -41.92 7.32 7.60 6.95 11.41 7.25 11.87 19.67
Altman Z-Score
3.53 3.58 3.54 1.60 1.92 1.94 2.21 2.29 2.24 2.04 2.26
Noncontrolling Interest Sharing Ratio
0.07% 0.07% 0.01% 0.33% 0.51% 0.46% 0.43% 0.41% 0.32% 0.23% 0.22%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.26 1.18 1.02 1.03 0.94 0.91 0.89 0.95 0.86 0.81 0.84
Quick Ratio
0.62 0.60 0.49 0.55 0.52 0.53 0.55 0.62 0.59 0.56 0.57
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-8,070 7,649 5,779 -48,585 11,214 -3,906 17,346 16,757 -6,189 9,186 10,414
Operating Cash Flow to CapEx
366.17% 455.98% 417.47% 435.20% 522.91% 651.01% 724.80% 593.22% 442.96% 327.47% 375.67%
Free Cash Flow to Firm to Interest Expense
-9.63 4.44 5.44 -18.55 3.60 -0.90 5.87 7.33 -2.33 3.72 3.34
Operating Cash Flow to Interest Expense
10.19 5.89 7.54 3.38 4.13 3.65 6.18 7.07 5.05 3.69 3.41
Operating Cash Flow Less CapEx to Interest Expense
7.41 4.60 5.73 2.61 3.34 3.09 5.33 5.88 3.91 2.56 2.50
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
1.84 1.90 1.95 1.33 1.23 1.19 1.26 1.40 1.50 1.48 1.59
Accounts Receivable Turnover
14.21 14.76 14.58 12.63 13.79 12.99 12.65 12.47 11.45 10.40 10.55
Inventory Turnover
9.78 10.19 10.40 10.27 12.44 12.20 13.24 10.69 11.70 11.42 11.84
Fixed Asset Turnover
16.40 17.73 18.06 17.98 21.95 21.80 22.91 0.00 0.00 28.48 30.84
Accounts Payable Turnover
18.06 18.99 18.59 18.33 21.76 20.31 20.27 14.38 14.60 13.40 13.19
Days Sales Outstanding (DSO)
25.69 24.72 25.03 28.90 26.47 28.09 28.85 29.26 31.88 35.10 34.61
Days Inventory Outstanding (DIO)
37.33 35.82 35.10 35.53 29.34 29.92 27.57 34.16 31.20 31.97 30.82
Days Payable Outstanding (DPO)
20.21 19.22 19.63 19.91 16.77 17.97 18.01 25.38 25.00 27.24 27.67
Cash Conversion Cycle (CCC)
42.81 41.32 40.50 44.52 39.04 40.04 38.41 38.04 38.09 39.82 37.76
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
62,159 60,907 62,778 109,659 107,280 121,439 114,184 103,324 119,806 116,972 110,328
Invested Capital Turnover
2.77 2.89 2.99 2.26 2.37 2.35 2.48 2.97 3.21 3.15 3.54
Increase / (Decrease) in Invested Capital
13,821 -1,252 1,871 46,881 -2,379 14,159 -7,255 -10,860 16,482 -2,834 -6,644
Enterprise Value (EV)
109,650 91,095 85,084 107,529 127,411 132,214 164,315 144,961 139,654 97,193 135,034
Market Capitalization
84,687 67,018 59,997 56,095 83,995 80,164 125,206 112,426 96,309 55,781 99,920
Book Value per Share
$33.59 $34.54 $37.21 $57.15 $49.09 $53.01 $56.87 $54.39 $59.42 $60.04 $59.25
Tangible Book Value per Share
($13.35) ($14.00) ($14.21) ($55.93) ($37.67) ($31.56) ($25.05) ($23.96) ($34.23) ($34.20) ($28.18)
Total Capital
64,706 64,365 64,697 131,972 132,650 153,105 149,734 140,823 154,280 156,899 153,595
Total Debt
27,464 27,531 27,002 73,429 68,480 83,404 74,353 69,054 77,644 81,169 78,213
Total Long-Term Debt
26,267 25,615 22,181 71,444 64,699 77,964 70,148 67,276 74,672 75,426 74,145
Net Debt
24,917 24,073 25,083 51,116 43,110 51,738 38,803 32,235 43,170 41,242 34,946
Capital Expenditures (CapEx)
2,332 2,224 1,918 2,037 2,457 2,437 2,520 2,727 3,031 2,781 2,832
Debt-free, Cash-free Net Working Capital (DFCFNWC)
4,639 3,250 3,595 -3,362 -7,276 -11,062 -16,119 -17,733 -19,814 -21,214 -20,508
Debt-free Net Working Capital (DFNWC)
7,186 6,708 5,402 3,219 780 -208 -3,594 -2,010 -8,359 -10,221 -9,910
Net Working Capital (NWC)
5,989 4,792 581 1,234 -3,001 -5,648 -7,799 -3,788 -11,331 -15,964 -13,978
Net Nonoperating Expense (NNE)
512 1,078 1,027 -1,108 2,204 3,061 2,102 1,570 1,925 1,766 2,042
Net Nonoperating Obligations (NNO)
24,917 24,073 25,083 51,116 43,110 51,738 38,803 31,555 43,170 41,242 34,946
Total Depreciation and Amortization (D&A)
2,092 2,475 2,479 2,718 4,371 4,441 4,486 4,224 4,366 4,597 4,606
Debt-free, Cash-free Net Working Capital to Revenue
3.03% 1.83% 1.95% -1.73% -2.83% -4.12% -5.52% -5.50% -5.54% -5.69% -5.10%
Debt-free Net Working Capital to Revenue
4.69% 3.78% 2.92% 1.65% 0.30% -0.08% -1.23% -0.62% -2.34% -2.74% -2.46%
Net Working Capital to Revenue
3.91% 2.70% 0.31% 0.63% -1.17% -2.10% -2.67% -1.17% -3.17% -4.28% -3.48%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 $0.00 ($0.57) $5.10 $5.48 $6.00 $3.16 $6.49 $3.67 $1.40
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 0.00 1.04B 1.30B 1.31B 1.32B 1.31B 1.29B 1.26B 1.27B
Adjusted Diluted Earnings per Share
$0.00 $0.00 $0.00 ($0.57) $5.08 $5.46 $5.95 $3.14 $6.47 $3.66 $1.39
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 0.00 1.04B 1.31B 1.31B 1.33B 1.32B 1.29B 1.26B 1.27B
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 0.00 1.30B 1.30B 1.31B 1.31B 1.28B 1.26B 1.26B 1.27B
Normalized Net Operating Profit after Tax (NOPAT)
5,751 6,397 7,795 7,119 9,005 10,253 11,448 12,078 10,934 7,306 8,401
Normalized NOPAT Margin
3.75% 3.60% 4.22% 3.66% 3.51% 3.82% 3.92% 3.75% 3.06% 1.96% 2.09%
Pre Tax Income Margin
5.62% 4.86% 4.47% 0.72% 3.50% 3.64% 3.61% 1.81% 3.12% 1.65% 0.53%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
11.28 6.02 8.79 1.54 3.89 3.25 4.57 3.55 5.20 3.49 1.53
NOPAT to Interest Expense
6.86 3.72 7.20 -0.65 2.84 2.36 3.42 2.58 3.87 2.57 1.21
EBIT Less CapEx to Interest Expense
8.50 4.73 6.98 0.76 3.10 2.69 3.71 2.36 4.06 2.36 0.62
NOPAT Less CapEx to Interest Expense
4.08 2.42 5.40 -1.43 2.05 1.80 2.56 1.39 2.73 1.45 0.30
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
30.08% 35.33% 30.94% -341.95% 39.26% 36.49% 32.86% 67.18% 37.43% 73.55% 196.59%
Augmented Payout Ratio
125.54% 119.20% 96.78% -341.95% 39.26% 36.49% 32.86% 148.07% 61.47% 139.47% 196.59%

Quarterly Metrics And Ratios for CVS Health

This table displays calculated financial ratios and metrics derived from CVS Health's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding
- - - - - - - - - - 1,272,211,063.00
DEI Adjusted Shares Outstanding
- - - - - - - - - - 1,272,211,063.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - - - 2.31
Growth Metrics
- - - - - - - - - - -
Revenue Growth
10.60% 11.89% 3.70% 2.60% 6.31% 4.15% 6.96% 8.42% 7.80% 8.17% 6.17%
EBITDA Growth
271.11% -4.55% -23.16% -3.21% -58.30% -21.84% 32.67% -15.14% -201.44% -7.12% 27.90%
EBIT Growth
195.72% -8.29% -33.79% -5.74% -76.91% -29.51% 48.17% -21.47% -471.18% -10.53% 38.51%
NOPAT Growth
200.92% -5.77% -36.99% -4.36% -79.68% -29.18% 42.21% -36.43% -499.03% 152.21% 52.96%
Net Income Growth
166.64% -12.22% -47.53% -7.63% -96.87% -20.71% 58.54% -42.70% -5,719.72% 80.10% 65.94%
EPS Growth
167.57% -11.17% -46.67% -4.73% -96.00% -18.24% 60.23% -43.26% -4,571.43% 77.69% 63.12%
Operating Cash Flow Growth
-70.23% -35.04% -34.08% -47.72% -127.43% 170.56% -7.08% -38.59% 206.85% 82.26% -6.74%
Free Cash Flow Firm Growth
-279.58% -202.66% -30.19% 511.97% 87.45% 133.32% -260.48% 383.97% 385.17% 141.36% 174.39%
Invested Capital Growth
16.60% 15.95% -5.16% 1.50% 1.97% -2.37% 13.57% -1.20% -6.06% -5.68% -4.34%
Revenue Q/Q Growth
0.95% 4.51% -5.73% 3.16% 4.60% 2.39% -3.20% 4.57% 4.00% 2.74% -4.98%
EBITDA Q/Q Growth
10.99% -6.41% -24.18% 22.89% -52.18% 75.42% 28.70% -21.40% -157.16% 260.63% 77.22%
EBIT Q/Q Growth
14.00% -8.54% -32.37% 33.67% -72.08% 179.23% 42.16% -29.16% -231.99% 167.31% 120.08%
NOPAT Q/Q Growth
14.94% -7.80% -36.71% 42.59% -75.58% 221.33% 27.09% -36.26% -253.29% 303.10% -22.92%
Net Income Q/Q Growth
18.34% -9.62% -45.09% 57.30% -95.98% 2,185.92% 9.80% -43.15% -493.88% 173.26% 1.16%
EPS Q/Q Growth
18.24% -9.14% -44.65% 60.23% -95.04% 1,757.14% 8.46% -43.26% -491.25% 173.80% -0.43%
Operating Cash Flow Q/Q Growth
-54.03% -197.05% 286.00% -37.00% -124.12% 349.66% 144.95% -58.36% -58.04% 325.88% 25.34%
Free Cash Flow Firm Q/Q Growth
-14,193.14% -2.41% 151.11% -91.70% -388.92% 372.02% -346.15% 125.02% 70.24% 130.23% -24.14%
Invested Capital Q/Q Growth
0.87% 4.17% -15.59% 14.44% 1.34% -0.26% -1.81% -0.45% -3.65% 0.15% -0.42%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
39.08% 60.59% 14.20% 45.20% 44.52% 71.89% 46.02% 45.40% 44.55% 44.12% 44.79%
EBITDA Margin
5.39% 4.83% 3.88% 4.63% 2.11% 3.62% 4.82% 3.62% -1.99% 3.11% 5.80%
Operating Margin
4.11% 3.60% 2.57% 3.34% 0.87% 2.42% 3.57% 2.41% -3.12% 2.00% 4.66%
EBIT Margin
4.14% 3.62% 2.60% 3.36% 0.90% 2.45% 3.60% 2.44% -3.09% 2.03% 4.69%
Profit (Net Income) Margin
2.52% 2.18% 1.27% 1.94% 0.07% 1.66% 1.88% 1.02% -3.88% 2.77% 2.94%
Tax Burden Percent
75.02% 75.67% 71.14% 75.65% 67.62% 76.34% 68.09% 61.51% 114.59% 215.88% 75.09%
Interest Burden Percent
81.33% 79.68% 68.82% 76.15% 12.25% 88.84% 76.93% 68.34% 109.46% 63.24% 83.57%
Effective Tax Rate
24.98% 24.33% 28.86% 24.35% 32.38% 23.66% 31.91% 38.49% 0.00% -115.88% 24.91%
Return on Invested Capital (ROIC)
10.04% 8.73% 6.35% 7.98% 1.87% 5.83% 8.52% 4.98% -7.56% 15.26% 12.70%
ROIC Less NNEP Spread (ROIC-NNEP)
8.56% 7.37% 4.76% 6.67% 0.68% 5.39% 6.93% 3.81% -11.97% 10.97% 11.11%
Return on Net Nonoperating Assets (RNNOA)
4.01% 3.71% 2.03% 3.68% 0.38% 2.99% 2.97% 1.93% -6.40% 5.53% 5.02%
Return on Equity (ROE)
14.05% 12.44% 8.37% 11.66% 2.25% 8.81% 11.49% 6.91% -13.96% 20.79% 17.73%
Cash Return on Invested Capital (CROIC)
-5.54% -5.55% 14.30% 6.56% 4.15% 7.76% -6.21% 6.59% 6.89% 9.16% 8.90%
Operating Return on Assets (OROA)
5.96% 5.42% 3.83% 4.86% 1.32% 3.63% 5.39% 3.69% -4.80% 3.21% 7.53%
Return on Assets (ROA)
3.64% 3.27% 1.88% 2.80% 0.11% 2.46% 2.83% 1.55% -6.02% 4.39% 4.72%
Return on Common Equity (ROCE)
14.00% 12.40% 8.35% 11.63% 2.25% 8.79% 11.46% 6.89% -13.93% 20.74% 17.69%
Return on Equity Simple (ROE_SIMPLE)
11.64% 0.00% 9.94% 9.61% 6.69% 0.00% 6.82% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
2,768 2,553 1,616 2,304 563 1,808 2,297 1,464 -2,245 4,559 3,514
NOPAT Margin
3.08% 2.72% 1.83% 2.53% 0.59% 1.85% 2.43% 1.48% -2.18% 4.31% 3.50%
Net Nonoperating Expense Percent (NNEP)
1.48% 1.35% 1.58% 1.31% 1.19% 0.44% 1.59% 1.17% 4.41% 4.30% 1.59%
Return On Investment Capital (ROIC_SIMPLE)
- 1.65% - - - 1.15% 1.47% 0.92% -1.47% 2.97% 2.28%
Cost of Revenue to Revenue
60.92% 39.41% 85.80% 54.80% 55.48% 28.11% 53.98% 54.60% 55.45% 55.88% 55.21%
SG&A Expenses to Revenue
11.00% 11.20% 11.64% 11.33% 11.06% 10.67% 11.65% 11.34% 10.97% 10.84% 10.90%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
34.97% 57.00% 11.64% 41.86% 43.64% 69.47% 42.45% 43.00% 47.66% 42.12% 40.13%
Earnings before Interest and Taxes (EBIT)
3,712 3,395 2,296 3,069 857 2,393 3,402 2,410 -3,181 2,141 4,712
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
4,839 4,529 3,434 4,220 2,018 3,540 4,556 3,581 -2,047 3,288 5,827
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.15 1.26 1.36 0.98 1.04 0.74 1.10 1.12 1.30 1.33 1.17
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.25 0.27 0.28 0.20 0.21 0.15 0.22 0.22 0.24 0.25 0.22
Price to Earnings (P/E)
9.89 11.54 13.73 10.20 15.60 12.09 16.01 19.05 202.23 56.52 30.89
Dividend Yield
3.56% 3.23% 3.17% 4.35% 4.18% 6.00% 3.97% 3.90% 3.56% 3.38% 3.74%
Earnings Yield
10.11% 8.66% 7.28% 9.81% 6.41% 8.27% 6.25% 5.25% 0.49% 1.77% 3.24%
Enterprise Value to Invested Capital (EV/IC)
1.10 1.17 1.26 0.99 1.03 0.83 1.07 1.08 1.20 1.22 1.12
Enterprise Value to Revenue (EV/Rev)
0.36 0.39 0.35 0.31 0.33 0.26 0.32 0.32 0.34 0.34 0.30
Enterprise Value to EBITDA (EV/EBITDA)
6.84 7.67 7.44 6.70 8.49 7.36 8.54 9.00 13.72 14.40 11.55
Enterprise Value to EBIT (EV/EBIT)
8.91 10.10 10.09 9.15 12.54 11.28 12.60 13.60 26.29 28.30 20.22
Enterprise Value to NOPAT (EV/NOPAT)
12.06 13.57 13.65 12.34 17.00 15.30 17.45 19.92 182.55 35.82 24.55
Enterprise Value to Operating Cash Flow (EV/OCF)
8.93 10.40 11.72 14.14 26.15 10.67 13.98 16.29 14.50 12.69 11.90
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 8.59 15.14 25.00 10.58 0.00 16.26 16.86 12.97 12.31
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
1.05 1.01 0.87 1.09 1.08 1.07 1.03 1.04 1.09 1.04 0.98
Long-Term Debt to Equity
1.02 0.97 0.78 1.04 1.00 1.00 0.95 0.92 1.02 0.98 0.95
Financial Leverage
0.47 0.50 0.43 0.55 0.55 0.55 0.43 0.51 0.53 0.50 0.45
Leverage Ratio
3.32 3.22 3.36 3.39 3.37 3.30 3.34 3.35 3.43 3.35 3.29
Compound Leverage Factor
2.70 2.57 2.31 2.58 0.41 2.93 2.57 2.29 3.75 2.12 2.75
Debt to Total Capital
51.26% 50.33% 46.38% 52.17% 51.82% 51.73% 50.70% 51.03% 52.20% 50.92% 49.61%
Short-Term Debt to Total Capital
1.39% 1.93% 4.66% 2.38% 3.66% 3.66% 3.63% 5.81% 3.48% 2.65% 1.67%
Long-Term Debt to Total Capital
49.86% 48.40% 41.72% 49.79% 48.16% 48.07% 47.08% 45.22% 48.72% 48.27% 47.94%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.11% 0.11% 0.13% 0.12% 0.10% 0.11% 0.12% 0.11% 0.12% 0.11% 0.12%
Common Equity to Total Capital
48.63% 49.56% 53.49% 47.72% 48.07% 48.16% 49.18% 48.86% 47.68% 48.97% 50.27%
Debt to EBITDA
4.26 4.27 3.74 4.81 5.69 6.14 5.53 5.90 8.29 8.34 7.18
Net Debt to EBITDA
2.20 2.37 1.57 2.39 2.97 3.12 2.63 2.69 3.85 3.73 3.03
Long-Term Debt to EBITDA
4.14 4.10 3.36 4.59 5.29 5.71 5.14 5.23 7.74 7.91 6.94
Debt to NOPAT
7.50 7.54 6.86 8.86 11.39 12.78 11.30 13.06 110.35 20.75 15.26
Net Debt to NOPAT
3.88 4.19 2.88 4.39 5.95 6.49 5.38 5.94 51.22 9.27 6.43
Long-Term Debt to NOPAT
7.30 7.25 6.17 8.45 10.59 11.87 10.49 11.57 102.99 19.67 14.74
Altman Z-Score
2.00 2.10 2.09 2.02 2.00 1.96 2.09 2.07 2.07 2.22 2.28
Noncontrolling Interest Sharing Ratio
0.34% 0.32% 0.26% 0.31% 0.22% 0.23% 0.24% 0.23% 0.23% 0.22% 0.23%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
0.86 0.86 0.81 0.86 0.80 0.81 0.82 0.80 0.83 0.84 0.87
Quick Ratio
0.60 0.59 0.54 0.60 0.54 0.56 0.59 0.58 0.59 0.57 0.61
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-13,602 -13,929 7,120 591 -1,706 4,642 -11,426 2,858 4,866 11,203 8,499
Operating Cash Flow to CapEx
498.35% -289.35% 695.46% 484.17% -111.19% 242.19% 613.19% 312.52% 114.04% 432.40% 500.47%
Free Cash Flow to Firm to Interest Expense
-19.63 -20.19 9.94 0.81 -2.27 17.38 -14.55 3.75 6.21 14.24 10.98
Operating Cash Flow to Interest Expense
3.92 -3.82 6.85 4.22 -0.99 6.97 5.80 2.49 1.02 4.31 5.49
Operating Cash Flow Less CapEx to Interest Expense
3.13 -5.14 5.86 3.35 -1.88 4.09 4.86 1.69 0.13 3.31 4.39
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
1.44 1.50 1.48 1.45 1.46 1.48 1.50 1.51 1.55 1.59 1.60
Accounts Receivable Turnover
11.74 11.45 11.92 11.73 10.68 10.40 10.55 10.59 9.85 10.55 10.12
Inventory Turnover
13.89 11.70 17.76 18.21 16.97 11.42 12.41 12.73 11.87 11.84 12.83
Fixed Asset Turnover
27.12 0.00 27.86 27.91 28.65 28.48 29.27 29.91 30.83 30.84 31.51
Accounts Payable Turnover
17.37 14.60 23.42 21.87 19.75 13.40 13.84 13.47 12.99 13.19 13.48
Days Sales Outstanding (DSO)
31.09 31.88 30.62 31.11 34.19 35.10 34.60 34.47 37.06 34.61 36.07
Days Inventory Outstanding (DIO)
26.28 31.20 20.55 20.04 21.51 31.97 29.42 28.68 30.74 30.82 28.44
Days Payable Outstanding (DPO)
21.01 25.00 15.58 16.69 18.48 27.24 26.38 27.10 28.11 27.67 27.07
Cash Conversion Cycle (CCC)
36.35 38.09 35.58 34.46 37.22 39.82 37.63 36.05 39.70 37.76 37.44
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
115,010 119,806 101,131 115,732 117,279 116,972 114,854 114,338 110,168 110,328 109,869
Invested Capital Turnover
3.26 3.21 3.47 3.16 3.18 3.15 3.51 3.36 3.47 3.54 3.63
Increase / (Decrease) in Invested Capital
16,370 16,482 -5,504 1,713 2,269 -2,834 13,723 -1,394 -7,111 -6,644 -4,985
Enterprise Value (EV)
126,017 139,654 127,687 114,117 120,565 97,193 122,472 123,279 132,084 135,034 122,988
Market Capitalization
85,344 96,309 100,524 73,315 78,230 55,781 84,547 86,320 94,844 99,920 90,575
Book Value per Share
$57.88 $59.42 $58.70 $59.69 $59.57 $60.04 $61.02 $61.17 $57.50 $59.25 $60.88
Tangible Book Value per Share
($36.24) ($34.23) ($36.57) ($35.57) ($35.09) ($34.20) ($32.40) ($31.66) ($30.38) ($28.18) ($26.01)
Total Capital
152,865 154,280 138,294 157,022 155,898 156,899 156,414 158,369 152,953 153,595 154,078
Total Debt
78,355 77,644 64,144 81,911 80,792 81,169 79,304 80,818 79,843 78,213 76,441
Total Long-Term Debt
76,223 74,672 57,694 78,180 75,082 75,426 73,634 71,618 74,515 74,145 73,861
Net Debt
40,500 43,170 26,981 40,621 42,173 41,242 37,744 36,787 37,058 34,946 32,232
Capital Expenditures (CapEx)
545 911 705 638 670 768 743 607 698 784 849
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-25,466 -19,814 -22,485 -23,965 -21,254 -21,214 -22,754 -23,486 -21,490 -20,508 -20,811
Debt-free Net Working Capital (DFNWC)
-9,278 -8,359 -9,396 -7,703 -11,574 -10,221 -10,100 -9,313 -10,258 -9,910 -9,009
Net Working Capital (NWC)
-11,410 -11,331 -15,846 -11,434 -17,284 -15,964 -15,770 -18,513 -15,586 -13,978 -11,589
Net Nonoperating Expense (NNE)
503 506 492 536 492 185 515 451 1,745 1,636 557
Net Nonoperating Obligations (NNO)
40,500 43,170 26,981 40,621 42,173 41,242 37,744 36,787 37,058 34,946 32,232
Total Depreciation and Amortization (D&A)
1,127 1,134 1,138 1,151 1,161 1,147 1,154 1,171 1,134 1,147 1,115
Debt-free, Cash-free Net Working Capital to Revenue
-7.32% -5.54% -6.23% -6.60% -5.76% -5.69% -6.00% -6.07% -5.45% -5.10% -5.10%
Debt-free Net Working Capital to Revenue
-2.67% -2.34% -2.60% -2.12% -3.14% -2.74% -2.67% -2.41% -2.60% -2.46% -2.21%
Net Working Capital to Revenue
-3.28% -3.17% -4.39% -3.15% -4.69% -4.28% -4.16% -4.79% -3.96% -3.48% -2.84%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$1.76 $1.59 $0.88 $1.41 $0.07 $1.31 $1.41 $0.81 ($3.13) $2.31 $2.31
Adjusted Weighted Average Basic Shares Outstanding
1.29B 1.29B 1.26B 1.26B 1.26B 1.26B 1.26B 1.27B 1.27B 1.27B 1.27B
Adjusted Diluted Earnings per Share
$1.75 $1.59 $0.88 $1.41 $0.07 $1.30 $1.41 $0.80 ($3.13) $2.31 $2.30
Adjusted Weighted Average Diluted Shares Outstanding
1.29B 1.29B 1.27B 1.26B 1.26B 1.26B 1.26B 1.27B 1.27B 1.27B 1.28B
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
1.29B 1.26B 1.26B 1.26B 1.26B 1.26B 1.27B 1.27B 1.27B 1.27B 1.28B
Normalized Net Operating Profit after Tax (NOPAT)
2,777 2,553 1,616 2,304 1,353 1,808 2,297 1,464 1,763 1,478 3,514
Normalized NOPAT Margin
3.09% 2.72% 1.83% 2.53% 1.42% 1.85% 2.43% 1.48% 1.71% 1.40% 3.50%
Pre Tax Income Margin
3.36% 2.88% 1.79% 2.56% 0.11% 2.18% 2.77% 1.67% -3.38% 1.28% 3.92%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
5.36 4.92 3.21 4.19 1.14 8.96 4.33 3.16 -4.06 2.72 6.09
NOPAT to Interest Expense
3.99 3.70 2.26 3.15 0.75 6.77 2.93 1.92 -2.86 5.79 4.54
EBIT Less CapEx to Interest Expense
4.57 3.60 2.22 3.32 0.25 6.09 3.39 2.36 -4.95 1.72 4.99
NOPAT Less CapEx to Interest Expense
3.21 2.38 1.27 2.28 -0.14 3.89 1.98 1.12 -3.75 4.80 3.44
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
35.50% 37.43% 43.44% 45.20% 66.15% 73.55% 64.32% 75.32% 792.06% 196.59% 117.26%
Augmented Payout Ratio
76.10% 61.47% 84.54% 87.12% 126.47% 139.47% 64.24% 75.30% 792.06% 196.59% 117.26%

Financials Breakdown Chart

Key Financial Trends

Here is a concise, investor-focused takeaway on CVS Health (CVS) using the latest four years of quarterly data provided. The focus is on trends in revenue, profitability, cash flow, and balance sheet fundamentals to help gauge ongoing performance and financial flexibility.

  • Top-line growth: Operating revenue rose from about $83.8 billion in Q4 2022 to about $105.7 billion in Q4 2025, representing roughly a 26% increase over the period.
  • Profitability: Net income to common shareholders climbed from about $2.334 billion in Q4 2022 to about $2.943 billion in Q4 2025, indicating improved bottom-line profitability in the latest year.
  • Cash generation (operating): Net cash from continuing operating activities improved to about $3.394 billion in Q4 2025, up from roughly $1.86 billion in the prior year (Q4 2024), signaling stronger cash generation in the most recent quarter.
  • Operating income trend: Total operating income in Q4 2025 was about $2.112 billion, marking an uptick versus the prior quarter and indicating stabilization of core operations in the latest period.
  • Shareholder returns: CVS continued a stable dividend program, with cash dividends per share around $0.665 in 2025 quarters, supporting income-oriented investors.
  • Balance sheet expansion: Total assets grew from roughly $253.2 billion at end of 2024 to about $255.3 billion by mid-2025, reflecting ongoing asset base expansion.
  • Impairment and charges: Notable one-time impairment charges of $5.725 billion were recognized in multiple 2025 quarters, which affect reported profitability but are non-operational and typically excluded from ongoing earnings comparisons.
  • Earnings volatility by quarter: A notable swing occurred in 2025, with a substantial quarterly net loss in Q3 2025 (continuous operations) followed by a robust recovery in Q4 2025, illustrating near-term earnings volatility within the year.
  • Leverage: Long-term debt remained very high, around $60.5–$60.6 billion in mid-2025, suggesting substantial leverage and potential constraints on financial flexibility.
  • Cash balance dynamics: Net change in cash and equivalents was negative in several quarters (for example, about -$2.673 billion in Q3 2025 and around -$0.64 billion in Q4 2025), highlighting ongoing cash outflows related to investing/financing activity despite operating cash generation.
05/25/26 10:24 AM ETAI Generated. May Contain Errors.

CVS Health Financials - Frequently Asked Questions

According to the most recent income statement we have on file, CVS Health's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

CVS Health's net income were at $1.73 billion at the end of 2025, a 62.3% decrease from 2024, and a 67.0% decrease since 2015. View CVS Health's forecast to see where analysts expect CVS Health to go next.

CVS Health's total operating income in 2025 was $4.66 billion, based on the following breakdown:
  • Total Gross Profit: $180.90 billion
  • Total Operating Expenses: $176.24 billion

Over the last 10 years, CVS Health's total revenue changed from $153.29 billion in 2015 to $402.07 billion in 2025, a change of 162.3%.

CVS Health's total liabilities were at $178.16 billion at the end of 2025, a 0.4% increase from 2024, and a 222.8% increase since 2015.

In the past 10 years, CVS Health's cash and equivalents has ranged from $1.70 billion in 2017 to $12.95 billion in 2022, and is currently $8.45 billion as of their latest financial filing in 2025.

Over the last 10 years, CVS Health's book value per share changed from 33.59 in 2015 to 59.25 in 2025, a change of 76.4%.



Financial statements for NYSE:CVS last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners